➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Medtronic
McKinsey
Colorcon
AstraZeneca

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

Litigation Details for Takeda Pharmaceutical Company Limited v. Mylan, Inc. (S.D.N.Y. 2012)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Takeda Pharmaceutical Company Limited v. Mylan, Inc. (S.D.N.Y. 2012)

Docket   Start Trial Date Filed 2012-03-20
Court District Court, S.D. New York Date Terminated 2014-04-17
Cause M 22-1 Designation by U.S. Attorney of individual to accept service of summons and complaint Assigned To Denise Cote
Jury Demand None Referred To
Parties ANDRX LABS, LLC; MYLAN PHARMACEUTICALS, INC; MYLAN, INC.; TAKEDA GLOBAL RESEARCH AND DEVELOPMENT CENTER, INC.; TAKEDA PHARMACEUTICAL COMPANY LIMITED; TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.; WATSON PHARMACEUTICALS, INC.
Patents 6,099,859; 6,166,043; 6,172,090; 6,495,162; 6,790,459; 6,866,866; 7,785,627; 7,919,116; 7,959,946
Attorneys Arthur H. Stroyd , Jr.; David G. Conlin; Gary E Hood; Gary P. Hunt; Karen M Zelle; Kathleen B. Carr; Keith J. Grady; Matthew J Bresnahan; Matthew Thomas Logue; Richard L. Byrne; Tung-On Kong
Link to Docket External link to docket
Small Molecule Drugs cited in Takeda Pharmaceutical Company Limited v. Mylan, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Takeda Pharmaceutical Company Limited v. Mylan, Inc. (S.D.N.Y. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-01-06 1 20. United States Patent No. 6,099,859 (“the ‘859 patent”), entitled “Controlled Release Oral Tablet…the ‘859 patent, ‘162 patent, ‘459 patent, ‘866 patent, ‘627 patent, ‘116 patent and ‘946 patent (collectively…under the ‘584 patent, the ‘043 patent, and the ‘090 patent (collectively, “Takeda Patents”). 20…licensed under the ‘584 patent, ‘043 patent and ‘090 patent (collectively, “Takeda Patents”) in connection with… The Patents in Suit 13. United States Patent No. 5,965,584 (“the ‘584 patent”), entitled External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
McKesson
Mallinckrodt
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.